A new report outlines the sharp cost increase associated with a NSCLC drug’s move from second-line to first-line treatment, and suggests payers work with manufacturers to address treatment pricing.
Chemotherapy may be the “boomer” to millennial-esque new cancer treatments, but there is a reason the old standard became that way, and isn’t likely to be replaced anytime soon.
There are a lot of ideas about ways to increase the value of cancer care, but personalized treatments may be the most significant and immediate.
A holistic approach provides value and creates plans that support the wide-ranging needs of cancer patients and their families.
As the proposed Radiation Oncology Model innovative payment model looms on the horizon, Anne Hubbard, director of health policy for the American Society for Radiation Oncology, talks about the main elements and complex finer points of the model, as well as what it will take for its success.
Researchers suggest changing cancer drug regimens could save money without sacrificing quality.
Proposed as an alternative to CMS’ Oncology Care Model, the Community Oncology Alliance is developing its Oncology Care Model 2.0 with the hopes of creating a better, more efficient payment and treatment system for cancer care.
In order to develop more effective cancer treatments, researchers are turning to precision medicine to evaluate patient tumor responses.
The high cost of targeted cancer therapies creates a “financial toxicity” for patients that has crippling effects.
Palliative care offers value and patient-centered care to lung cancer patients.